恩格列净治疗2型糖尿病的临床综合评价

打开文本图片集

【中图分类号】 R977.1+5 【文献标识码】A

【Abstract】 Objective To conduct a multidimensional and multi-level evaluation of the comprehensive clinical value of empagliflozin in the treatment of type 2 diabetes melitus.Methods Based on the National Essential Medicines List （2Ol8 Edition），dapagliflozin was selected as the control. A comprehensive clinical evaluation index system was established through literature review， focus group interviews and in-depth expert interviews， encompassing six dimensions： safety， efficacy， economy， suitability，innovation，and accessbility. The Delphi method and hierarchical direct weighting method were used to screen indicators and determine their weights.Evidence for each indicator was colected and integrated both qualitatively and quantitatively through literature research，real-world studies，and pharmacoeconomic evaluations.Experts scored the indicators based on the collected evidence，and a total score for the comprehensive clinical evaluation of empagliflozin was calculated by combining these scores with indicator weights，followed by a comparative analysis with dapagliflozin. Results A comprehensive clinical evaluation of empagliflozin in thetreatment of type 2 diabetes melitus was successfully established，consisting of6 primary indicators，14 secondary indicators，and 41 tertiary indicators.The overall evaluation score for empagliflozin was 90.35，and 89.47 for dapagliflozin. Conclusion The comprehensive clinical value of empagliflozin in the treatment of type 2 diabetes melitus is slightly higher than that of dapagliflozin.This finding can serveas a reference for rational clinical drug use and related decision-making.

【Keywords】Empagliflozin; Dapagliflozin; Type 2 diabetes mellitus; Comprehensive clinical evaluation

中国作为糖尿病患病人数最多的国家之一，承受着糖尿病对医疗卫生体系和社会带来的巨大负担[]。（剩余26181字）